Search results for "Smoldering Multiple Myeloma"

showing 3 items of 3 documents

Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes

2021

Monoclonal gammopathy of ocular significance (MGOS) is a rare subset of monoclonal gammopathy of clinical significance occurring secondary to plasma cell disorders and causing ocular manifestations. We identified 23 patients with paraproteinemic keratopathy (PPK) in the setting of monoclonal gammopathy of unknown significance (MGUS, 10), smoldering multiple myeloma (SMM, 3) or multiple myeloma (MM, 10). Many of these patients with PPK (11/23) presented decreased vision. All patients with MM and 40% of those with other diagnoses such as SMM and MGUS received systemic therapy with or without autologous stem cell transplantation. Four eyes of four patients were treated by penetrating keratopla…

Smoldering Multiple MyelomaCancer Researchmedicine.medical_specialtyVisual acuitygenetic structuresMonoclonal gammopathy of clinical significancemonoclonal gammopathy of ocular significanceTreatment outcomeParaproteinemiasPlasma cellMonoclonal Gammopathy of Undetermined SignificanceTransplantation AutologousSystemic therapyGastroenterologyMonoclonal gammopathy of clinical significance; monoclonal gammopathy of ocular significance; multiple myeloma; paraproteinemic keratopathyCorneal DiseasesAutologous stem-cell transplantationhemic and lymphatic diseasesInternal medicinemedicineHumansClinical significanceMultiple myelomabusiness.industryHematopoietic Stem Cell TransplantationHematologymedicine.diseaseeye diseasesMonoclonal gammopathyparaproteinemic keratopathyTreatment Outcomemedicine.anatomical_structureOncologyNeoplasm Recurrence Localmedicine.symptomMultiple MyelomabusinessLeukemia & Lymphoma
researchProduct

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

2022

Abstract Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor cells (CTC), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model. Experimental Design: We report the outcomes of 150 patients with SMM enrolled in the iMMunocell study, in which serial assessment of tumor and immune cells in PB was performed every 6 months for a period of 3 years since enrollment. Resul…

Smoldering Multiple MyelomaCancer ResearchmyelomaOncologyDisease ProgressionHumansImmunoglobulin Light ChainsPrognosisMultiple MyelomaRisk Assessmentcirculating tumor cellimmune profile.Clinical Cancer Research
researchProduct

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

2022

Key Points FlowCT is a new computational workspace for unveiling cellular diversity and objectively identifying biomarkers in large immune monitoring studies.FlowCT identified T-cell biomarkers predictive of malignant transformation and survival in SMM and active MM data sets.

Smoldering Multiple MyelomaOncologymedicine.medical_specialtyImmunobiology and ImmunotherapyT cellMyeloma2423ImmunophenotypingImmune systemMaintenance therapyBone MarrowInternal medicineHumansMedicineBiomarker discoveryMultiple myelomaCancer immunologybusiness.industryHematologymedicine.diseaseFlow Cytometrymedicine.anatomical_structureSmouldering myelomaBone marrowbusinessBiomarkersmyeloma flow cytometry single cell smouldering myeloma
researchProduct